Optiscan Imaging (OIL) Conference at Emerging ASX Gems Conference summary

Business overview and technology

• ASX-listed medical device company with patented high-resolution live microscopic imaging system, proven in clinical studies and product launches over decades.

• Manufactures in Melbourne, expanded into the US with a commercial hub, and products are ISO 13485 certified.

• Core technology is a fluorescent-based confocal endomicroscope, providing real-time, submicron pathology images for clinical use.

• Platform is tissue-agnostic, imaging any soft tissue in humans or animals, and correlates well with histopathology.

• Technology eliminates need for repeat surgeries and physical biopsies by enabling real-time diagnosis.

Product development and clinical pipeline

• Expanding clinical device portfolio for hospitals, in-office, and veterinary markets.

• Developing software solutions, including remote telepathology streaming and AI-based applications for oral, breast, and GI imaging.

• Next-gen flexible GI endomicroscope and robotic-compatible systems in development, aiming for minimally invasive and precision medicine applications.

• Minimum viable product for telepathology service expected by June 2025; AI applications to follow hardware releases.

• Oral imaging platform (InVivage) and surgical device (InView) to undergo clinical testing and regulatory approval in the next 12 months, with breast cancer as a key indication.

Strategic partnerships and market expansion

• Collaborations with Mayo Clinic (robotics), University of Minnesota (veterinary), and University Medical Center Mainz (GI endoscopy) to drive product development.

• Additional device for pathology labs to be unveiled and pushed through regulatory cycle in FY 2025.

• Expanding US presence with Rochester office and business development managers on both coasts; outsourced BDM team in Europe and growing sales in China.

• Life sciences product sold to pharma, research institutions, and universities.